BR9812133A - Análogos de gaba para prevenir e tratar danos gastrintestinais - Google Patents

Análogos de gaba para prevenir e tratar danos gastrintestinais

Info

Publication number
BR9812133A
BR9812133A BR9812133-2A BR9812133A BR9812133A BR 9812133 A BR9812133 A BR 9812133A BR 9812133 A BR9812133 A BR 9812133A BR 9812133 A BR9812133 A BR 9812133A
Authority
BR
Brazil
Prior art keywords
prevent
gaba analogs
gastrointestinal damage
treat gastrointestinal
treat
Prior art date
Application number
BR9812133-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Antonio Guglietta
Charles Price Taylor Jr
Jiayuan Ren
Willian Patrick Watson
Michael Francis Rafferty
Laurent Diop
Maria Chovet
Lionel Bueno
Hilary J Little
Original Assignee
Warner Lambert Co
Regents For The University Of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27369092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9812133(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co, Regents For The University Of filed Critical Warner Lambert Co
Publication of BR9812133A publication Critical patent/BR9812133A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
BR9812133-2A 1997-08-20 1998-08-18 Análogos de gaba para prevenir e tratar danos gastrintestinais BR9812133A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5675397P 1997-08-20 1997-08-20
US7479498P 1998-02-16 1998-02-16
US8293698P 1998-04-24 1998-04-24
PCT/US1998/017082 WO1999008671A1 (en) 1997-08-20 1998-08-18 Gaba analogs to prevent and treat gastrointestinal damage

Publications (1)

Publication Number Publication Date
BR9812133A true BR9812133A (pt) 2000-07-18

Family

ID=27369092

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812133-2A BR9812133A (pt) 1997-08-20 1998-08-18 Análogos de gaba para prevenir e tratar danos gastrintestinais

Country Status (25)

Country Link
US (2) US6242488B1 (https=)
EP (1) EP1009399B1 (https=)
JP (1) JP4681116B2 (https=)
KR (2) KR100609359B1 (https=)
AT (1) ATE461698T1 (https=)
AU (2) AU8668598A (https=)
BR (1) BR9812133A (https=)
CA (1) CA2297163C (https=)
CO (1) CO4960645A1 (https=)
CY (1) CY1109981T1 (https=)
DE (1) DE69841574D1 (https=)
DK (1) DK1009399T3 (https=)
ES (1) ES2341154T3 (https=)
HU (1) HUP0004551A3 (https=)
IL (1) IL134164A (https=)
IS (1) IS2749B (https=)
MY (1) MY155223A (https=)
NO (1) NO327983B1 (https=)
NZ (1) NZ502729A (https=)
PE (1) PE107299A1 (https=)
PL (1) PL194125B1 (https=)
PT (1) PT1009399E (https=)
TW (2) TWI251485B (https=)
UY (1) UY25148A1 (https=)
WO (2) WO1999008670A1 (https=)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
WO1999012537A1 (en) 1997-09-08 1999-03-18 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
EP1031350A1 (en) * 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
US6451857B1 (en) 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
DE60022333T2 (de) * 1999-04-09 2006-07-06 Euro-Celtique S.A. Natrium kanalblocker zusammensetzungen und deren verwendung
EP1840117A1 (en) * 1999-06-10 2007-10-03 Warner-Lambert Company LLC Mono- and disubstituted 3-propyl gamma-aminobutyric acids
AU767119B2 (en) 1999-07-22 2003-10-30 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes
FR2801217B1 (fr) * 1999-11-24 2002-12-06 Aventis Pharma Sa Association de riluzole et de gabapentine et son utilisation comme medicament
JP2003533223A (ja) 2000-05-16 2003-11-11 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー α２δ２カルシウムチャネルサブユニットの発現細胞株
WO2002028881A1 (en) 2000-10-06 2002-04-11 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
EP1361847A2 (en) 2000-10-06 2003-11-19 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
EP1226820A1 (en) 2001-01-26 2002-07-31 Warner-Lambert Company Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ATE540678T1 (de) 2001-06-11 2012-01-15 Xenoport Inc Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen
US7420002B2 (en) 2001-06-11 2008-09-02 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
IL160523A0 (en) 2001-09-03 2004-07-25 Newron Pharm Spa PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN alpha-AMINOAMIDE AND ITS ANALGESIC USE
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
WO2003077902A1 (en) 2002-02-19 2003-09-25 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
RU2286151C2 (ru) * 2002-02-22 2006-10-27 Уорнер-Ламберт Компани Ллс Комбинации альфа-2-дельта-лиганда с селективным ингибитором циклооксигеназы-2
AU2003222033A1 (en) 2002-03-20 2003-10-08 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
WO2003099338A2 (en) 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
AU2003247042A1 (en) * 2002-07-10 2004-02-02 Warner-Lambert Company Llc Gastrointestinal compositions comprising gaba derivatives
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
WO2004052360A1 (en) 2002-12-11 2004-06-24 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
MXPA05006209A (es) * 2002-12-13 2005-08-19 Warner Lambert Co Pregabalina y sus derivados para el tratamiento de fibromialgia y otros trastornos relacionados.
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
WO2004054560A1 (en) * 2002-12-13 2004-07-01 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
WO2004078734A1 (en) 2003-03-07 2004-09-16 Warner-Lambert Company Llc TETRAZOLE AND OXADIAZOLONE SUBSTITUTED β-AMINO ACID DERIVATIVES
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
KR20060119971A (ko) 2003-09-11 2006-11-24 제노포트 인코포레이티드 Ｇａｂａ 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방
AU2004274002B2 (en) 2003-09-17 2011-04-28 Arbor Pharmaceuticals, Llc Treating or preventing restless legs syndrome using prodrugs of GABA analogs
PT1677767E (pt) 2003-10-14 2011-10-13 Xenoport Inc Forma cristalina de análogo de ácido gama-aminobutírico
US20050176680A1 (en) 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
RU2335342C2 (ru) * 2004-03-12 2008-10-10 Уорнер-Ламберт Компани Ллс C1-симметричные бисфосфиновые лиганды и их применение в асимметрическом синтезе прегабалина
EP1735324B1 (en) * 2004-04-01 2008-08-20 Warner-Lambert Company LLC Preparation of p-chirogenic phospholanes and their use in asymetric synthesis
MXPA06014228A (es) * 2004-06-21 2007-02-14 Warner Lambert Co Preparacion de pregabalina y compuestos relacionados.
ATE471147T1 (de) * 2004-09-10 2010-07-15 Newron Pharm Spa Verwendung von (r)-(halogenbenzyloxy)-benzylamino-propanamiden als natrium- und/oder calciumkanal- selektive modulatoren
CA2584338C (en) 2004-11-04 2013-08-06 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
EP1963280B1 (en) * 2005-12-22 2015-10-28 Newron Pharmaceuticals S.p.A. 2-phenylethylamino derivatives as calcium and/or sodium channel modulators
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
WO2008073257A1 (en) * 2006-12-08 2008-06-19 Xenoport, Inc. Use of prodrugs of gaba analogs for treating diseases
CA2703472A1 (en) * 2007-10-26 2009-04-30 The Scripps Research Institute Methods for treating substance dependence
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
EP2250148B1 (en) 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
CA2706575C (en) 2008-01-25 2015-07-14 Xenoport, Inc. Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
CN105330603A (zh) 2008-10-08 2016-02-17 凯飞药业公司 Gaba偶联物及其使用方法
ES2654331T3 (es) * 2009-06-22 2018-02-13 Wyeth Llc Comprimidos de ibuprofeno de sodio y procedimientos de fabricación de composiciones farmacéuticas que incluyen ibuprofeno de sodio
WO2011141923A2 (en) 2010-05-14 2011-11-17 Lupin Limited Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin
WO2012059797A1 (en) 2010-11-04 2012-05-10 Lupin Limited Process for synthesis of (s) - pregabalin
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
CA2903000C (en) 2013-01-28 2021-10-12 Hector L. Lopez Methods of improving tolerability, pharmacodynamics, and efficacy of .beta.-alanine and use therefor
CN105997970A (zh) * 2015-12-16 2016-10-12 南昌大学 γ-氨基丁酸在制备胃粘膜保护剂中的应用
WO2017177160A1 (en) * 2016-04-07 2017-10-12 Nevakar Llc Formulation for use in a method of treatment of pain
JP7249670B2 (ja) 2017-10-03 2023-03-31 ネヴァカー インジェクテーブルズ インコーポレイテッド アセトアミノフェン－プレガバリン組み合わせ及び疼痛を処置する方法
CN112424158A (zh) 2018-05-14 2021-02-26 昌郁医药公司 萘普生和普瑞巴林的1-(酰氧基)-烷基氨基甲酸酯药物缀合物的结晶形式
CN116999560A (zh) * 2022-04-30 2023-11-07 武汉思瓴生物科技有限公司 可治疗疼痛的药物组合及其应用
AU2024220546A1 (en) * 2023-02-17 2025-09-04 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid for gastrointestinal tract disorders and as an immunomodulatory agent

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE634102A (https=)
DE1963925C3 (de) 1969-12-20 1975-07-10 Desitin-Werk, Carl Klinke Gmbh, 2000 Hamburg Verfahren zur Herstellung von N hoch 3-Carbalkoxyderivaten des 5,5-Diphenylhydantoins
JPS54110334A (en) 1978-02-16 1979-08-29 Fuji Chem Ind Co Ltd Novel compounded anodyne and antiiinflammatory agent
US4158581A (en) 1978-04-14 1979-06-19 Westinghouse Electric Corp. Method of making magnetic component for direct current apparatus
JPS61221121A (ja) 1985-03-27 1986-10-01 Nitto Electric Ind Co Ltd テ−プ製剤
US4694010A (en) 1985-08-16 1987-09-15 New York University Anticonvulsant compositions and method
AU2929489A (en) 1987-12-22 1989-07-19 John W. FERKANY Dextrorphan potentiator for anticonvulsant composition and method
AU9137091A (en) 1990-11-27 1992-06-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
GB9108362D0 (en) 1991-04-18 1991-06-05 Radoslavov Alexander A pharmaceutical composition suitable for alleviation of headaches,migraine and other painful conditions
JP3856816B2 (ja) * 1992-05-20 2006-12-13 ノースウェスターン ユニヴァーシティ 抗発作治療用のｇａｂａ及びｌ−グルタミン酸類縁体
US5234929A (en) 1992-07-20 1993-08-10 William Chelen Method of treating motion sickness with anticonvulsants and antitussive agents
JPH06100468A (ja) 1992-09-25 1994-04-12 Kibun Food Chemifa Co Ltd 徐放性組成物
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
JPH06227969A (ja) 1993-02-02 1994-08-16 Masayasu Sugihara 薬品の腸溶性改善方法およびそれにより得られた薬品組成物
US5420270A (en) 1993-10-07 1995-05-30 G. D. Searle & Co. Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5352638A (en) 1994-02-22 1994-10-04 Corning Incorporated Nickel aluminosilicate glass-ceramics
FI970865A7 (fi) 1994-09-02 1997-03-14 Univ Virginia Commonwealth Ei-huumaavaa kipulääkeainetta sekä kivun poistamisen tehostajaa sisält ävä, kipua lievittävä koostumus
GB9420784D0 (en) * 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
CN1046199C (zh) 1994-12-13 1999-11-10 凌吉安 复方消炎止痛霜剂
CA2264182A1 (en) * 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
ATE361909T1 (de) * 1996-10-23 2007-06-15 Warner Lambert Co Substituierte gamma-aminobuttersäurederivate als arzneimittel
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage

Also Published As

Publication number Publication date
NO327983B1 (no) 2009-11-02
PT1009399E (pt) 2010-05-21
WO1999008670A1 (en) 1999-02-25
EP1009399A1 (en) 2000-06-21
HUP0004551A2 (hu) 2001-05-28
IL134164A (en) 2005-05-17
DE69841574D1 (de) 2010-05-06
PL338705A1 (en) 2000-11-20
US6426368B2 (en) 2002-07-30
IS2749B (is) 2011-08-15
CA2297163C (en) 2001-11-20
MY155223A (en) 2015-09-30
CO4960645A1 (es) 2000-09-25
KR100609359B1 (ko) 2006-08-04
EP1009399B1 (en) 2010-03-24
KR20050116168A (ko) 2005-12-09
DK1009399T3 (da) 2010-05-31
US6242488B1 (en) 2001-06-05
AU8668598A (en) 1999-03-08
WO1999008671A1 (en) 1999-02-25
TW570794B (en) 2004-01-11
ATE461698T1 (de) 2010-04-15
CY1109981T1 (el) 2014-09-10
JP4681116B2 (ja) 2011-05-11
NZ502729A (en) 2002-10-25
AU9293098A (en) 1999-03-08
IL134164A0 (en) 2001-04-30
PE107299A1 (es) 1999-12-19
NO20000786D0 (no) 2000-02-17
NO20000786L (no) 2000-02-17
JP2001515033A (ja) 2001-09-18
TW200412938A (en) 2004-08-01
IS5361A (is) 2000-01-25
HUP0004551A3 (en) 2002-11-28
PL194125B1 (pl) 2007-04-30
CA2297163A1 (en) 1999-02-25
US20010014698A1 (en) 2001-08-16
KR20010023084A (ko) 2001-03-26
TWI251485B (en) 2006-03-21
UY25148A1 (es) 1999-01-26
ES2341154T3 (es) 2010-06-15

Similar Documents

Publication Publication Date Title
BR9812133A (pt) Análogos de gaba para prevenir e tratar danos gastrintestinais
DK0840606T3 (da) Små di- og trivalente molekyler som selectininhibitorer
FI945426L (fi) GABA- ja L-glutamiinihappoanalogit kohtauksenvastaiseen käsittelyyn
ATE380049T1 (de) Kombinationen enthaltend cgmp-pde5-hemmer.
BR9710994A (pt) Derivados anticonvulsivos úteis no tratamento de obesidade.
BR0009564A (pt) Utilização de inibidores da cyp2d6 em terapias de combinação
AR038434A2 (es) Compuesto 14,15-dihidro-16-oxoparahercuamida y compuestos 2-desoxo de parahercuamida y marcfortina
NO990857D0 (no) Fosfinsyreamider som matriks-metallprotease-inhibitorer
NO984524D0 (no) Amfipatiske molekyler som kolesterol- og andre lipoidopptaksinhibitorer
DK0705100T3 (da) Terapeutiske substituerede guanidiner
BR9805544C1 (pt) Uso de um composto.
AR021777A1 (es) UNA COMPOSICIoN PARA ACONDICIONAR, ACLARAR E ILUMINAR EL CABELLO Y UN MÉTODO PARA ACONDICIONAR, ACLARAR E ILUMINAR EL CABELLO.
WO2003020273A3 (en) Pharmaceutical composition comprising gabapentin or an analogue thereof and an $g(a)-aminoamide and its analgesic use
NO983530D0 (no) Dihydrobenzofuran og relaterte forbindelser anvendelig som anti-inflammatoriske midler
BR9907655A (pt) Derivados de ácido di-hidróxi-hexanóico
NO922167D0 (no) Aminodukter som korrosjonshemmere
DE69625230D1 (de) Thrombininhibitoren
EP0974351A3 (en) Medicament for preventing and treating gastrointestinal damage
EA199900579A1 (ru) Применение ингибиторов комт для производства лекарственного средства для профилактики сосудистых дисфункций при диабете
BR9712546A (pt) Adjuvante, notadamente sob a forma de uma emulsão contendo um cátion metálico trivalente e composição vacinal que a compreende
DK1042288T3 (da) Tripeptidyl-peptidase inhibitorer
BR9810387A (pt) (s) 3, 4, 5-trimetoxibenzoato de 2-metilamino-2-fenil-n-butila, e sua aplicação para o tratamento de dor crÈnica
DE59409706D1 (de) Cycloalkylcarbonsäureanilide
EA200100039A1 (ru) Способы увеличения уровней ацетилхолина
AR015371A1 (es) Uso de un derivado de 7alfa-etinil-estrano y un metodo para inhibir el proceso de la ateroesclerosis que comprende administrar a un mamifero dicho derivado

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO REQUISITO DE NOVIDADE ( ART. 8O COMBINADO COM ART. 11 DA LEI 9.279/96 )

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.